Daiichi Sankyo and AstraZeneca's ENHERTU Receives EMA Validation, Significantly Improves Survival in HER2 Positive Breast Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Newsfilter
- Clinical Trial Results: The DESTINY-Breast09 phase 3 trial demonstrated that the combination of ENHERTU and pertuzumab significantly improved progression-free survival (PFS) for patients with HER2 positive metastatic breast cancer, providing a new treatment option.
- EMA Approval Progress: The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU, marking the commencement of the scientific review process, which is expected to lead to improved treatment outcomes for patients.
- Global Collaboration: Daiichi Sankyo and AstraZeneca have been jointly developing ENHERTU since 2019, aiming to leverage their combined strengths to accelerate the market introduction of this new drug and enhance patient treatment outcomes.
- Market Potential: ENHERTU has been approved in over 90 countries worldwide, indicating its broad applicability in treating HER2 positive breast cancer, and is expected to significantly improve patient survival rates and quality of life.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 102.75 USD with a low forecast of 95.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 93.990
Low
95.00
Averages
102.75
High
108.00
Current: 93.990
Low
95.00
Averages
102.75
High
108.00
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
